Topical exosome treatments are rapidly evolving from experimental innovation to clinical mainstay in aesthetic medicine.
Among the most rigorously validated in this category is Resiliélle Age Zero Exosomes, now available exclusively in Australia through Enesi Australia. Combining scientific precision, ethical sourcing and clinical versatility, the Age Zero range has been developed to deliver consistent, measurable outcomes across a broad spectrum of skin and hair concerns.
Origin & potency
The defining feature of Resiliélle Age Zero lies in its source material. These exosomes are derived exclusively from Wharton’s Jelly of full-term, healthy umbilical cords – considered the gold-standard source of ‘zero-age’ mesenchymal stem cells (hWJ-MSCs) due to their potency, immune privilege and regenerative capacity. Every donation is ethically sourced and screened under stringent FDA 21 CFR 1271 regulations.
Low-passage culturing (≤4) further helps to preserve the cells’ youthful properties, producing exosomes with high bioactivity and stability. Unlike adipose- or bone marrow-derived stem cells from older donors, hWJ-MSCs are claimed to retain their ‘zero-age’ regenerative profile, offering a high-yield, immune-privileged source ideal for consistent, high-purity exosome production.
Scientific validation & transparency
Each batch of Age Zero exosomes is counted, characterised and verified in FDA-registered and CLIA-certified laboratories in New York. The product undergoes rigorous testing for sterility, endotoxin levels, mycoplasma, bioburden and infectious diseases. Structural integrity is confirmed via Harvard Medical School transmission electron microscopy (TEM), which demonstrates the correct size (30–150 nm), intact bilipid membrane, and the presence of hallmark exosomal surface markers CD9, CD63 and CD81.
This level of transparency extends to the clinic: each vial is supplied with a Certificate of Conformity and donor traceability, enabling practitioners to verify product quality at every stage.
Frozen, not freeze-dried
Resiliélle products are never lyophilised. Instead, they are preserved in ultra-cold clinical-grade saline to maintain the structural integrity and biological activity of growth factors, proteins and microRNAs. Freeze-drying can compromise the delicate bilipid membrane, reducing efficacy. By preserving exosomes in their natural state, Resiliélle helps to ensure maximum bioactivity and reproducibility in clinical settings.
Clinical performance & outcomes
Clinical data from a 100-participant study demonstrate the measurable benefits of Age Zero exosomes used topically in conjunction with microneedling at concentrations ranging from 5 to 100 billion.1 Participants reported:
• 85 percent reduction in post-treatment redness
• 86 percent improvement in fine lines and wrinkles
• 89 percent improvement in pigmentation and skin spots
• 90 percent improvement in skin texture and radiance.
These results are supported by a growing body of clinical imagery and case reports documenting improvements in hair density and pigment restoration, scar minimisation (including burns and trauma), and accelerated post-procedure healing across laser, RF and microneedling applications.
Patients have described expedited recovery, improved skin tone and texture, and enhanced radiance.
WHAT’S INSIDE AGE ZERO™?
Resiliélle Age Zero is a topical regenerative cosmetic containing:
- Natural growth factors and proteins
- Ceremides and nucleic acids
- Cellular repair vesicles (true exosomes)
- Signal molecules to help restore skin and follicles.
Versatility in clinic
Designed for topical use only, Age Zero exosomes integrate seamlessly into existing treatment protocols. They can be used with microneedling, radiofrequency and laser devices, peels, hair restoration and scar prevention. Their acellular, preservative-free formulation makes them suitable for patients seeking a non-injectable regenerative solution.
The multi-dose vial format – unique to Resiliélle – allows clinicians to deliver precise dosing from a single vial, improving efficiency and profitability. The product can be drawn into syringes for pinpoint application, dispensed via droppers for more targeted use, or applied through sprayers and oxygen infusion for broader coverage. Once thawed, it can be stored in the refrigerator for future use within the recommended three-month period.
Defining clinical-grade standards
One of the most compelling differentiators of Resiliélle Age Zero is the level of scientific rigour underpinning the product. True exosomes must meet three key criteria: correct size range, presence of CD9/CD63/CD81 markers, and intact bilipid membrane structure. Resiliélle meets all three, validated by NanoSight particle analysis, immunogold TEM imaging and independent laboratory testing.
This clinical-grade standard not only enhances patient outcomes but also offers practitioners confidence in product integrity – an important consideration in a rapidly expanding and often inconsistent exosome marketplace.
1. Data on file. Resilience Cosmetics LLC 2024.
Resiliélle Age Zero exosomes are distributed in Australia by Enesi. For more information, visit resilielle.com.au, enesi.com.au or contact info@enesi.com.au.
